Nyxoah (NASDAQ:NYXH) & DarioHealth (NASDAQ:DRIO) Head-To-Head Survey

DarioHealth (NASDAQ:DRIO) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for DarioHealth and Nyxoah, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	0	0	1	0	3.00
Nyxoah	0	0	5	0	3.00

DarioHealth currently has a consensus price target of $4.00, indicating a potential upside of 471.18%. Nyxoah has a consensus price target of $17.00, indicating a potential upside of 63.93%. Given DarioHealth’s higher probable upside, analysts clearly believe DarioHealth is more favorable than Nyxoah.

Profitability

This table compares DarioHealth and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DarioHealth	-205.62%	-72.16%	-40.74%
Nyxoah	-1,043.93%	-51.68%	-40.11%

Insider & Institutional Ownership

33.4% of DarioHealth shares are held by institutional investors. 16.5% of DarioHealth shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

DarioHealth has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.

Valuation and Earnings

This table compares DarioHealth and Nyxoah”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$20.35 million	1.17	-$59.43 million	($0.94)	-0.75
Nyxoah	$5.08 million	50.89	-$46.77 million	($1.87)	-5.55

Nyxoah has lower revenue, but higher earnings than DarioHealth. Nyxoah is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.

Summary

DarioHealth beats Nyxoah on 7 of the 13 factors compared between the two stocks.

About DarioHealth

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.